Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression: (Consensus Statement)
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To provide expert recommendations for the safe and effective application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depressive disorder (MDD). PARTICIPANTS: Participants included a group of 17 expert clinicians and researchers with expertise in the clinical application of rTMS, representing both the National Network of Depression Centers (NNDC) rTMS Task Group and the American Psychiatric Association Council on Research (APA CoR) Task Force on Novel Biomarkers and Treatments. EVIDENCE: The consensus statement is based on a review of extensive literature from 2 databases (OvidSP MEDLINE and PsycINFO) searched from 1990 through 2016. The search terms included variants of major depressive disorder and transcranial magnetic stimulation. The results were limited to articles written in English that focused on adult populations. Of the approximately 1,500 retrieved studies, a total of 118 publications were included in the consensus statement and were supplemented with expert opinion to achieve consensus recommendations on key issues surrounding the administration of rTMS for MDD in clinical practice settings. CONSENSUS PROCESS: In cases in which the research evidence was equivocal or unclear, a consensus decision on how rTMS should be administered was reached by the authors of this article and is denoted in the article as "expert opinion." CONCLUSIONS: Multiple randomized controlled trials and published literature have supported the safety and efficacy of rTMS antidepressant therapy. These consensus recommendations, developed by the NNDC rTMS Task Group and APA CoR Task Force on Novel Biomarkers and Treatments, provide comprehensive information for the safe and effective clinical application of rTMS in the treatment of MDD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Repetitive transcranial magnetic stimulation (rTMS) is an effective method used in clinical practice for treating patients with MDD. 408”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [408]
In the citing paper
“Most clinical rTMS treatments for MDD occur daily (one rTMS session per day) and are applied using scalp-based targeting of DLPFC. These standard treatments are only modestly effective, even in the general MDD population (17, 24–31).”
In the citing paper
“rTMS of the left side of the dorsolateral prefrontal cortex (DLPFC) at 10 Hz is a well-tolerated, evidence-based treatment for TRD.5”
In the citing paper
“While this intensity is consistent with current recommendations for standard rTMS,5 there is no current consensus on the optimal intensity for TBS and other studies have used lower intensities.12”
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Rossi, S., Hallett, M., Rossini, P. M., & Pascual-Leone, A. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2009.08.016 · Cited by 5,367
NON-INVASIVE MAGNETIC STIMULATION OF HUMAN MOTOR CORTEX
Barker, A. T., Jalinous, R., & Freeston, I. L. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92413-4 · Cited by 4,460
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Wassermann, E. M. (1998) · Electroencephalography and Clinical Neurophysiology/Evoked Potentials Section · doi:10.1016/s0168-5597(97)00096-8 · Cited by 2,293
Lefaucheur, J.-P., André-Obadia, N., Antal, A., Ayache, S. S., Baeken, C., Benninger, D. H., Cantello, R. M., Cincotta, M., de Carvalho, M., De Ridder, D., et al. (2014) · Clinical Neurophysiology · doi:10.1016/j.clinph.2014.05.021 · Cited by 2,119
O’Reardon, J. P., Solvason, H. B., Janicak, P. G., Sampson, S., Isenberg, K. E., Nahas, Z., McDonald, W. M., Avery, D., Fitzgerald, P. B., Loo, C., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.018 · Cited by 1,910
Self-citationUsing the International 10-20 EEG System for Positioning of Transcranial Magnetic Stimulation
Herwig, U., Satrapi, P., & Schönfeldt-Lecuona, C. (2003) · Brain Topography · doi:10.1023/b:brat.0000006333.93597.9d · Cited by 1,098
George, M. S., Lisanby, S. H., Avery, D., McDonald, W. M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.46 · Cited by 1,092 · cited 1×
“…magnetic stimulation device package insert as well as in the US Food and Drug Administration (FDA) 510k application material. b In the study by George et al,10 patients underwent head magnetic resonance imaging with fiducials (vitamin E capsules), which resulted in 33.2% of patients having…”
BackgroundSelf-citation
Cited by
Items 101–200 of 690
Chen, L., Hudaib, A.-R., Hoy, K. E., & Fitzgerald, P. B. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.035 · Cited by 43
Cotovio, G., Oliveira-Maia, A. J., Paul, C., Viana, F. F., da Silva, D. R., Seybert, C., Stern, A. P., Pascual‐Leone, Á., & Press, D. Z. (2021) · Brain stimulation · doi:10.1016/j.brs.2021.07.013 · Cited by 51
“5 cm anteriorly to M1, on the corresponding parasagittal line, according to the available clinical recommendations [28].”
MethodInfluentialBrini, S., Brudasca, N. I., Hodkinson, A., Kaluzinska, K., Wach, A., Storman, D., Prokop-Dorner, A., Jemioło, P., & Bala, M. M. (2023) · Clinical Psychology Review · doi:10.1016/j.cpr.2022.102236 · Cited by 44
Age differences in resting state EEG and their relation to eye movements and cognitive performance
Stacey, J. E., Crook‐Rumsey, M., Sumich, A. L., Howard, C. J., Crawford, T. J., Livne, K., Lenzoni, S., & Badham, S. P. (2021) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2021.107887 · Cited by 48
Repetitive transcranial magnetic stimulation and its role in suicidality – A systematic review
Godi, S. M., Spoorthy, M. S., Purushotham, A., & Tikka, S. K. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102755 · Cited by 43
Markman, T. M., Pothineni, N. V. K., Zghaib, T., Smietana, J. J., McBride, D. A., Amankwah, N., Linn, K. A., Kumareswaran, R., Hyman, M. C., Arkles, J., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2021.6000 · Cited by 44
Leong, K., Chan, P., Ong, L., Zwicker, A., Willan, S., Lam, R. W. M., & McGirr, A. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720923064 · Cited by 46
EEG Phase Synchronization in Persons With Depression Subjected to Transcranial Magnetic Stimulation
Zuchowicz, U., Woźniak-Kwaśniewska, A., Szekely, D., Olejarczyk, E., & David, O. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01037 · Cited by 46
“of the origin of major depression disorder and the influence of rTMS on depression treatment has generated a great number of researches, including studies using EEG-based methods (Rossi et al., 2009; Gaynes et al., 2014; Lefaucheur et al., 2014; Brunoni et al., 2017; McClintock et al., 2018).”
MethodMadeo, G., Terraneo, A., Cardullo, S., Pérez, L. J. G., Cellini, N., Sarlo, M., Spagnolo, P. A., Leggio, L., Gallimberti, L., Bonci, A., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00158 · Cited by 48
Large-scale EEG neural network changes in response to therapeutic TMS
Gold, M. C., Yuan, S., Tirrell, E., Kronenberg, E. F., Kang, J. W. D., Hindley, L. E., Sherif, M. A., Brown, J. C., & Carpenter, L. L. (2022) · Brain stimulation · doi:10.1016/j.brs.2022.01.007 · Cited by 44
Self-citationA Meta-analysis of Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder
Steuber, E. R., & Mcguire, J. F. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.06.003 · Cited by 66
Siddiqi, S., Philip, N. S., Palm, S. T., Carreon, D. M., Arulpragasam, A. R., Barredo, J., Bouchard, H. C., Ferguson, M. A., Grafman, J. H., Morey, R. A., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01772-7 · Cited by 53
“…able to directly access deep regions such as the amygdala and anterior cingulate cortex, we compared this circuit with common TMS targets that have been used in different clinical trials for depression, including the mPFC, the ‘5 cm’ and EEG F3/F4 targets, and the ‘6 cm’ and Beam F3/F4 targets 68 .”
Noda, Y., Zomorrodi, R., Daskalakis, Z. J., Blumberger, D. M., & Nakamura, M. (2018) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2018.07.004 · Cited by 39
Walther, S., Alexaki, D., Schoretsanitis, G., Weiss, F., Vladimirova, I., Stegmayer, K., Strik, W. K., & Schäppi, L. (2020) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaa020 · Cited by 42
“53,54 Diagnoses were given by trained psychiatrists using the complete case files as well as the Mini International Neuropsychiatric Interview.”
Menardi, A., Dotti, L., Ambrosini, E., & Vallesi, A. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11236-2 · Cited by 49
“the “5 cm rule” [40] for the identification of the Dorsolateral Prefrontal Cortex—DLPFC), is targeted across patients regardless of their interindividual anatomical differences.”
BackgroundDalton, B., Lewis, Y. D., Bartholdy, S., Kekic, M., McClelland, J., Campbell, I. C., & Schmidt, U. H. (2020) · European Eating Disorders Review · doi:10.1002/erv.2766 · Cited by 42
Chou, P., Lin, K., Lu, M., Chang, H., Chu, C., Chang, W. H., Kishimoto, T., Sack, A. T., & Su, K. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.190 · Cited by 42
“highest level of efficacy for the treatment of depression [6,7].”
BackgroundPu, Z., Hou, Q., Yan, H., Lin, Y., & Guo, Z. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.11.062 · Cited by 43
An End-to-End Depression Recognition Method Based on EEGNet
Liu, B., Chang, H., Peng, K., & Wang, X. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864393 · Cited by 49
“Several different treatments are currently available, including a wide variety of antidepressant drugs (9–11), electroconvulsive therapy (ECT) (12), repetitive transcranial magnetic stimulation (rTMS) (13), and deep brain stimulation (DBS) (14).”
BackgroundFang, F. Z., Godlewska, B. R., Cho, R. Y., Savitz, S. I., Selvaraj, S., & Zhang, Y. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119465 · Cited by 38
“While the parameters are commonly used in clinical rTMS treatment [57, 58], they do not strictly follow the standard protocol by determining the stimulation amplitude based on the motor-evoked potentials (MEP) [80].”
BackgroundMethodPantazatos, S. P., Mclntosh, J. R., Saber, G. T., Sun, X., Doose, J., Faller, J., Lin, Y., Teves, J., Blankenship, A., Huffman, S. M., et al. (2023) · Brain stimulation · doi:10.1016/j.brs.2023.05.007 · Cited by 39
“We used the Beam F3 locator to mark the EEG F3 [26] location in DLPFC of each subject consistent with recent consensus guidelines [27, 26, 28].”
MethodSelf-citationThe influence of endogenous estrogen on high-frequency prefrontal transcranial magnetic stimulation
Chung, S. W., Thomson, C. J., Lee, S., Worsley, R., Rogasch, N. C., Kulkarni, J., Thomson, R. H., Fitzgerald, P. B., & Segrave, R. A. (2019) · Brain stimulation · doi:10.1016/j.brs.2019.05.007 · Cited by 41
Maffioletti, E., Minelli, A., Tardito, D., & Gennarelli, M. (2020) · Genes · doi:10.3390/genes11091089 · Cited by 39
Ni, H., Lin, H., Chen, Y., Hung, J., Wu, C., Wu, Y., Liang, H., Chen, R., Gau, S. S., & Huang, Y. (2021) · Biomedical Journal · doi:10.1016/j.bj.2021.07.008 · Cited by 40
“[44] McClintock SM, Reti IM, Carpenter LL, McDonald WM, Dubin M, Taylor SF, et al.”
BackgroundResultLi, X., Zhang, C., Tan, J., Ding, L., Wang, C., Wang, M., & Lin, Y. (2022) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.210134 · Cited by 39
Fitzgibbon, K. P., Plett, D., Chan, B., Hancock, R., Coyte, P. C., & Blumberger, D. M. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719890167 · Cited by 43
“rTMS is associated with reduced side effects and reduced costs for the health-care system, as it is completed almost entirely on an ambulatory basis without the need for anesthesia.(11) rTMS is not associated with cognitive impairment and may actually improve cognitive functions including both short- and long-term mem…”
BackgroundLooking Back at the Next 40 Years of ASD Neuroscience Research
McPartland, J. C., Lerner, M. D., Bhat, A. N., Clarkson, T., Jack, A., Koohsari, S., Matuskey, D., McQuaid, G. A., Su, W.-C., & Trevisan, D. A. (2021) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-021-05095-5 · Cited by 39
“RTMS is an effective evidence-based method for treating psychiatric conditions, such as major depressive disorder (McClintock et al. 2017), and, more recently, researchers have begun to investigate the therapeutic potential of rTMS in ASD (Abujadi et al.”
MethodKeller, M., Zweerings, J., Klasen, M., Zvyagintsev, M., Iglesias, J., Quiñones, R. M., & Mathiak, K. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.715898 · Cited by 36
“For instance, repetitive transcranical magnetic stimulation (rTMS) over the lPFC is an evidence-based treatment for depression which is successfully applied in treatment refractory depression (45, 46).”
BackgroundNeacsiu, A. D., Beynel, L., Powers, J., Szabo, S. T., Appelbaum, L. G., Lisanby, S. H., & LaBar, K. S. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000518957 · Cited by 38
Self-citationRoss, J. M., Sarkar, M., & Keller, C. J. (2022) · Human Brain Mapping · doi:10.1002/hbm.25990 · Cited by 36
“…rMT: Massimini et al., 2005; Rocchi et al., 2021), our suprathreshold stimulation protocol (120% rMT) better mimicked clinical stimulation parameters (McClintock et al., 2018), but is more difficult to mask (Biabani et al., 2019; Fuggetta et al., 2005; Ross et al., 2021; ter Braack et al., 2015).”
BackgroundSonmez, A. I., Küçüker, M. U., Lewis, C. P., Kolla, B. P., Camsari, D. D., Voort, J. L. V., Schak, K. M., Kung, S., & Croarkin, P. E. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109763 · Cited by 38
Treating major depression and comorbid disorders with transcranial magnetic stimulation
Thompson, L. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.025 · Cited by 35
Ariza-Salamanca, D. F., Corrales-Hernández, M. G., Pachón-Londoño, M. J., & Hernández-Duarte, I. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.993671 · Cited by 40
Zhang, J. J. Y., Ang, J., Saffari, S. E., Tor, P.-C., Lo, Y. L., & Wan, K. R. (2024) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2024.07.010 · Cited by 39
Hung, Y.-Y., Yang, L.-H., Stubbs, B., Li, D.-J., Tseng, P.-T., Yeh, T.-C., Chen, T.-Y., Liang, C.-S., & Chu, C.-S. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109850 · Cited by 33
The study of noninvasive brain stimulation using molecular brain imaging: A systematic review
Tremblay, S., Tuominen, L. J., Zayed, V. K., Pascual‐Leone, Á., & Joutsa, J. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117023 · Cited by 40
Shao, D., Zhao, Z. N., Zhang, Y., Zhou, X., Zhao, L., Dong, M., Xu, F., Xiang, Y., & Luo, H. (2021) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x202010010 · Cited by 42
“For MDD, clinical consensus recommends high-frequency stimulation for the left dorsolateral prefrontal cortex (DLPFC) and low-frequency stimulation for the right DLPFC (29).”
BackgroundBalderston, N. L., Beer, J. C., Seok, D., Makhoul, W., Deng, Z., Girelli, T., Teferi, M., Smyk, N. J., Jaskir, M., Oathes, D. J., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01110-6 · Cited by 37
“…prefrontal cortex (dlPFC) has been cleared by the US Food and Drug Administration (FDA), and has been shown to be effective as an antidepressant treatment in treatment resistant depression, a patient population not responsive to or tolerant of previous antidepressant medication trials (4–6).”
BackgroundLefaucheur, J., Colzi, C., Hollander, E., Pampaloni, I., Ameringen, M. V., Baeken, C., Fusar‐Poli, P., Arango, C., Fontenelle, L. F., Batail, J.-M. V., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106140 · Cited by 33
Padula, C. B., Tenekedjieva, L., McCalley, D. M., Al-Dasouqi, H., Hanlon, C. A., Williams, L. M., Kozel, F. A., Knutson, B. D., Durazzo, T. C., Yesavage, J. A., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.893833 · Cited by 39
“Extensive research supports the clinical efficacy of TMS for psychiatric disorders, most commonly for major depressive disorder (MDD), after FDA approval in 2008 (81).”
BackgroundOberman, L. M., & Benussi, A. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.07.012 · Cited by 33
“Recent studies have also indicated potential predictive markers for treatment response, such as baseline motor cortex excitability and the presence of speci fi c genetic polymorphisms (95).”
BackgroundTozzi, L., Bertrand, C., Hack, L. M., Lyons, T., Olmsted, A. M., Rajasekharan, D., Chen, T., Berlow, Y. A., Yesavage, J. A., Lim, K. O., et al. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00271-9 · Cited by 35
“nature mental health https://doi.org/10.1038/s44220-024-00271-9”
InfluentialPrecision non-implantable neuromodulation therapies: a perspective for the depressed brain
Borrione, L., Bellini, H., Razza, L. B., Ganho-Ávila, A., Baeken, C., Brem, A., Busatto, G. F., Carvalho, A. F., Chekroud, A. M., Daskalakis, Z. J., et al. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0741 · Cited by 38
Self-citationSustained Modulation of Deep Brain Circuits with Focused Ultrasonic Waves
Webb, T. D., Wilson, M. G., Odéen, H., & Kubanek, J. (2022) · Brain stimulation · doi:10.1016/j.brs.2023.04.012 · Cited by 35
Oberman, L. M., Hynd, M., Nielson, D. M., Towbin, K. E., Lisanby, S. H., & Stringaris, A. K. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.642847 · Cited by 32
“Since its initial FDA clearance, in 2008, multiple TMS devices and protocols have also received clearance for adult MDD. Consensus guidelines have also been established by the National Network of Depression Centers and the American Psychiatric Association Council on Research (124).”
MethodInfluentialSelf-citationModulation of brain networks during MR-compatible transcranial direct current stimulation
Leaver, A. M., Gonzalez, S., Vasavada, M. M., Kubicki, A., Jog, M., Wang, D. J. J., Woods, R. P., Espinoza, R. T., Gollan, J. K., Parrish, T. B., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.118874 · Cited by 33
Gonsalves, M. A., White, T. L., Barredo, J., Fukuda, A. M., Joyce, H. E., Harris, A. D., & Carpenter, L. L. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103049 · Cited by 34
Self-citationBenster, L. L., Weissman, C. R., Stolz, L. A., Daskalakis, Z. J., & Appelbaum, L. G. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02673-2 · Cited by 36
“Over the last several decades, rTMS treatment parameters have been modi fi ed for enhanced clinical utility across a range of disorders [17].”
BackgroundAcupuncture may play a key role in anti-depression through various mechanisms in depression
Li, P., Zhao, J., Wei, X., Luo, L., Chu, Y., Zhang, T., Zhu, A., & Yan, J. (2024) · Chinese Medicine · doi:10.1186/s13020-024-00990-2 · Cited by 38
“For example, the non-invasive neuromodulation technology from rehabilitation discipline, Repetitive Transcranial Magnetic Stimulation (rTMS) has been proved to have a good effect on depression, but its cost is higher than that of ordinary antide-pressants [17].”
BackgroundFeffer, K., Lee, H. H., Wu, W., Etkin, A., Demchenko, I., Cairo, T., Mazza, F., Fettes, P., Mansouri, F., Bhui, K. S., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.038 · Cited by 32
Cabrera, L. Y., Miller, M. M. C., Achtyes, E. D., McCright, A. M., & Bluhm, R. L. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114612 · Cited by 31
“Approved TMS protocols typically involve four to five sessions per week for four to six weeks, equalling 20–30, 45-minute treatment sessions (Rasmussen, 2011), and our participants frequently identified time commitment as a potential barrier.”
BackgroundInfluentialPinot-Monange, A., Moisset, X., Chauvet, P., Grémeau, A., Comptour, A., Canis, M. J., Pereira, B., & Bourdel, N. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040508 · Cited by 33
“Repetitive TMS is approved for the treatment of depression and is highly effective [9,42].”
BackgroundCui, H., Jiang, L., Wei, Y., Li, W., Li, H., Zhu, J., Pang, J., Wang, J., & Li, C. (2019) · General Psychiatry · doi:10.1136/gpsych-2019-100051 · Cited by 27
“14 The US Food and Drug Administration has approved the high-frequency rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) in treating resistant major depressive disorder (MDD).”
Psychiatric Applications of Repetitive Transcranial Magnetic Stimulation
Marder, K. G., Barbour, T. A., Ferber, S., Idowu, O., & Itzkoff, A. (2022) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20210021 · Cited by 41
Tao, Y., Liang, Q., Zhang, F., Guo, S., Fan, L., & Zhao, F. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02480-w · Cited by 31
“…that modulates cortical activity through the application of a weak direct current of 1–2 mA [9]. rTMS is applied to the prefrontal cortex to induce magnetic fields that modulate functional connectivity within and between the two cortical networks, thereby alleviating depressive symptoms [10].”
Oostra, E., Jażdżyk, P., Vis, V., Dalhuisen, I., Hoogendoorn, A. W., Planting, C. H. M., van Eijndhoven, P., van der Werf, Y. D., van den Heuvel, O. A., & van Exel, E. R. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13768 · Cited by 35
Young, J. R., Smani, S., Mischel, N., Kritzer, M. D., Appelbaum, L. G., & Patkar, A. A. (2020) · Journal of Addictive Diseases · doi:10.1080/10550887.2020.1736756 · Cited by 31
Mehta, S. H., Downar, J. H., Mulsant, B. H., Voineskos, D., Daskalakis, Z. J., Weissman, C. R., Vila‐Rodriguez, F., & Blumberger, D. M. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13412 · Cited by 33
Functional connectivity of the cerebellar vermis in bipolar disorder and associations with mood
Saleem, A., Harmata, G., Jain, S., Voss, M. W., Fiedorowicz, J. G., Williams, A. J., Shaffer, J. J., Richards, J. G., Barsotti, E. J., Sathyaputri, L., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1147540 · Cited by 27
“While it is unclear if the same stimulation paradigm should be used as employed for the dorsal lateral prefrontal cortex (80), it is a potential novel therapeutic target that could help individuals with bipolar disorder to better maintain a euthymic mood state.”
BackgroundTheta-burst direct electrical stimulation remodels human brain networks
Huang, Y., Zelmann, R., Hadar, P., Peralta, J. D., Richardson, R. M., Williams, Z. M., Cash, S. S., Keller, C. J., & Paulk, A. C. (2024) · Nature Communications · doi:10.1038/s41467-024-51443-1 · Cited by 34
“It clearly adds to the understanding of the effects, underlying mechanisms and factors that impact on TBS.”
Maneeton, B., Maneeton, N., Woottiluk, P., & Likhitsathian, S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200221113134 · Cited by 28
“Secondly, since the rTMS regiment applied in those eligible studies was a lower number of pulse and sessions than the current consensus guidelines [49], its possibly affected the overall efficacy of MDD treatment.”
MacDuffie, K. E., Ransom, S. M., & Klein, E. P. (2021) · AJOB Neuroscience · doi:10.1080/21507740.2021.1896596 · Cited by 28
Baeken, C., van Beek, V., Vanderhasselt, M., Duprat, R., & Klooster, D. (2021) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.13380 · Cited by 25
Plewnia, C., Brendel, B., Schwippel, T., Nieratschker, V., Ethofer, T., Kammer, T., Padberg, F., Martus, P., & Fallgatter, A. J. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01280-w · Cited by 26
“The exclusion criteria of this study include the currently valid contraindications for rTMS treatment [4].”
BackgroundMethodMcNerney, M. W., Heath, A. M., Narayanan, S., & Yesavage, J. A. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215361 · Cited by 27
“Treating mice daily for 14 days fit with previous mouse rTMS protocols [24, 27, 28], whereas twice weekly for six weeks is designed to recapitulate clinical practice where patients cannot come to the clinic everyday but are encouraged to finish their regimen by six weeks [29].”
BackgroundPetrozzi, B. P., Insan, S., Spangemacher, M., Reinwald, J., Lamadé, E. K., Gilles, M., Deuschle, M., & Sartorius, A. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00514-0 · Cited by 29
Ren, J., Su, W., Zhou, Y. C., Han, K., Pan, R., Duan, X., Liu, J., Lu, H., Zhang, P., Zhang, W., et al. (2025) · Brain stimulation · doi:10.1016/j.brs.2025.02.009 · Cited by 29
“Lastly, we acknowledge the potential impact of post-stroke depression on cognitive improvement, especially since the DLPFC is a common target for depression treatments [57,58].”
Trevizol, A. P., & Blumberger, D. M. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1550 · Cited by 28
“The watchful waiting approach typically involves restimulation using the protocol from the acute course when a relapse is confirmed.(2) The first study that assessed re-stimulation reported that 84.”
BackgroundMethodInfluentialWieczorek, T., Kobyłko, A., Stramecki, F., Fila-Witecka, K., Beszłej, J. A., Jakubczyk, M. H., Piotrowski, P., Senczyszyn, A., Siwicki, D., Szcześniak, D. M., et al. (2020) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/115556 · Cited by 37
Case Series of Transcutaneous Magnetic Stimulation for Ventricular Tachycardia Storm
Markman, T. M., Hamilton, R. H., Marchlinski, F. E., & Nazarian, S. (2020) · JAMA · doi:10.1001/jama.2020.3833 · Cited by 25
Tong, J., Zhang, J., Jin, Y., Liu, W., Wang, H., Huang, Y., Shi, D., Zhu, M., Zhu, N., Zhang, T., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11060765 · Cited by 30
“In 2008, the US Food and Drug Administration (FDA) cleared the NeuroStar TMS Therapy System as the first device for rTMS treatment of MDD, and it has been adopted into clinical practice [19,20].”
He, J., Tang, Y., Lin, J., Faulkner, G., Tsang, H. W. H., & Chan, S. H. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03843-0 · Cited by 31
“In addition, a TMS procedure needs to be performed to correctly establish the optimal site of motor responses and individual motor thresholds to minimize adverse effects [11].”
BackgroundMethodSimultaneous Gut-Brain Electrophysiology Shows Cognition and Satiety Specific Coupling
Balasubramani, P. P., Walke, A., Grennan, G., Purpura, S., Perley, A. S., Ramanathan, D., Coleman, T. P., & Mishra, J. (2022) · Sensors · doi:10.3390/s22239242 · Cited by 34
Diagnosis and Management of Neuropathic Pain in Spine Diseases
Bielewicz, J., Kamieniak, M., Szymoniuk, M., Litak, J., Czyżewski, W., & Kamieniak, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041380 · Cited by 31
Bi, R., Zhao, Y., Li, S., Xu, F., Peng, W., Tan, S., & Zhang, D. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.064 · Cited by 27
Closed-loop neurostimulation for affective symptoms and disorders: An overview
Moreno, J. G., Biazoli, C. E., Baptista, A. F., & Trambaiolli, L. R. (2021) · Biological Psychology · doi:10.1016/j.biopsycho.2021.108081 · Cited by 26
Early Improvement Predicts Clinical Outcomes Similarly in 10 Hz rTMS and iTBS Therapy for Depression
Spitz, N. A., Pace, B., Eyck, P. T., & Trapp, N. T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.863225 · Cited by 26
“Resting motor threshold (RMT) was determined via right-handed thumb twitches in three of five trials while delivering stimulation to the left primary motor cortex via the Magventure MagPro X100 Figure 8 Butterfly Coil with Active Cooling (Magventure, Alpharetta, GA) (16).”
MethodInfluentialrTMS Therapy Reduces Hypofrontality in Patients With Depression as Measured by fNIRS
Kawabata, Y., Imazu, S., Matsumoto, K., Toyoda, K., Kawano, M., Kubo, Y., Kinoshita, S., Nishizawa, Y., & Kanazawa, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.814611 · Cited by 25
“Repetitive transcranial magnetic stimulation (rTMS) is efficacious for treating depression (7).”
BackgroundCaparelli, E. C., Abulseoud, O. A., Gu, H., Zhai, T., Schleyer, B., & Yang, Y. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.997259 · Cited by 28
“In general, depression treatment protocols employ high frequency (HF—10 to 20 Hz) rTMS to the left DLPFC (Polley et al., 2011; McClintock et al., 2018).”
BackgroundTranscranial Magnetic Stimulation in Conditions Other than Major Depressive Disorder
Becker, J. E., Shultz, E. K. B., & Maley, C. T. (2018) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2018.08.001 · Cited by 26
Singh, A., Erwin-Grabner, T., Goya-Maldonado, R., & Antal, A. (2020) · Neuropsychobiology · doi:10.1159/000502149 · Cited by 23
Gałecki, P., & Bliźniewska-Kowalska, K. M. (2019) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/115208 · Cited by 30
Miron, J., Voetterl, H., Fox, L., Hyde, M., Mansouri, F., Dees, S., Zhou, R., Sheen, J., Jodoin, V. D., Mir-Moghtadaei, A., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113790 · Cited by 26
Dehghani-Arani, F., Kazemi, R., Hallajian, A., Sima, S., Boutimaz, S., Hedayati, S., Koushamoghadam, S., Safarifard, R., & Salehinejad, M. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185358 · Cited by 28
Voineskos, A. N., Blumberger, D. M., Schifani, C., Hawco, C. S., Dickie, E. W., Rajji, T. K., Mulsant, B. H., Foussias, G., Wang, W., & Daskalakis, Z. J. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.11.011 · Cited by 24
Trevizol, A. P., Downar, J. H., Vila‐Rodriguez, F., Konstantinou, G., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Depression and Anxiety · doi:10.1002/da.23125 · Cited by 25
Cabrera, L. Y., Gilbert, M. M. C., McCright, A. M., Achtyes, E. D., & Bluhm, R. L. (2021) · Psychiatric Quarterly · doi:10.1007/s11126-021-09916-9 · Cited by 30
“This may be because few patient and public participants in the study were not aware of or familiar with TMS, which was surprising given its FDA approval for treating MDD, and the subsequent expansion of TMS clinics [11].”
BackgroundInfluentialMajumder, P., Balan, S., Gupta, V. K., Wadhwa, R., & Perera, T. D. (2021) · Cureus · doi:10.7759/cureus.14564 · Cited by 29
“Repetitive transcranial magnetic stimulation (rTMS) is a relatively new treatment modality that is gaining attention in the treatment of various conditions afflicting adults [11-13].”
BackgroundHussain, S., Chamoli, S., Fitzgerald, P. B., Gandhi, A., Gill, S., Sarma, S., & Loo, C. K. A. (2024) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674241249846 · Cited by 28
“…of rTMS can be found in a recent umbrella review of meta-analyses of randomised controlled trials investigating the effectiveness of all forms of non-invasive brain stimulation for depression (Razza et al., 2020) and internationally published consensus recommendations (McClintock et al., 2017).”
BackgroundMollica, A., Ng, E., Burke, M. J., Nestor, S. M., Lee, H. H., Rabin, J. S., Hamani, C., Lipsman, N., & Giacobbe, P. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.06.006 · Cited by 26
“…in a wide variety of neurological and psychiatric conditions [2], and its use has been endorsed in numerous international clinical guidelines as an evidence-based treatment for major depressive disorder (MDD) that has not responded to at least one adequate antidepressant medication trial [3 – 6].”
BackgroundStoby, K. S., Rafique, S. A., Oeltzschner, G., & Steeves, J. K. E. (2022) · Brain and Behavior · doi:10.1002/brb3.2478 · Cited by 32
Michel‐Flutot, P., de Jesus, I., Vanhee, V., Bourcier, C. H., Emam, L., Ouguerroudj, A., Lee, K., Zholudeva, L. V., Lane, M. A., Mansart, A., et al. (2022) · Biology · doi:10.3390/biology11030473 · Cited by 24
Wilke, S. A., Johnson, C. L., Corlier, J., Marder, K. G., Wilson, A. C., Pleman, C. M., & Leuchter, A. F. (2022) · Depression and Anxiety · doi:10.1002/da.23255 · Cited by 22
“Current safety guidelines do not rule out use of rTMS in patients taking psychostimulants and direct effects on cortical excitability have generally not been seen (McClintock et al., 2018; Minzenberg & Leuchter, 2019), and none of the subjects in this study suffered a seizure.”
BackgroundNicola, M. D., Pepe, M., Panaccione, I., Moccia, L., Janiri, L., & Sani, G. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230403080624 · Cited by 26
“Repetitive TMS is an evidence-based treatment for MDD [29] and promising evidence has been raising in the addiction field, especially for the treatment of substance use disorders [30].”
BackgroundAdvancing Neuroscience and Therapy: Insights into Genetic and Non-Genetic Neuromodulation Approaches
Zhi, W., Li, Y., Wang, L., & Hu, X. (2025) · Cells · doi:10.3390/cells14020122 · Cited by 27
“The current FDA-approved rTMS treatment mode is as follows: 10 Hz stimulation for 19–37.5 min per treatment at 120% of the resting motion threshold, 20–30 times a course, 5 times/week for 4–6 weeks; usually, a duration of 26–28 min produces the best treatment effects [152].”
InfluentialGharooni, A.-A., Kwon, B. K., Fehlings, M. G., Boerger, T. F., Rodrigues‐Pinto, R., Koljonen, P. A., Kurpad, S. N., Harrop, J. S., Aarabi, B., Rahimi‐Movaghar, V., et al. (2022) · Global Spine Journal · doi:10.1177/21925682211052920 · Cited by 21
Transcranial magnetic stimulation in the treatment of depression during pregnancy: a review
Hebel, T., Schecklmann, M., & Langguth, B. (2019) · Archives of Women s Mental Health · doi:10.1007/s00737-019-01004-z · Cited by 24
Exploratory study on neurochemical effects of low-intensity pulsed ultrasound in brains of mice
Guo, H., Baker, G. B., Hartle, K. D., Fujiwara, E., Wang, J., Zhang, Y., Xing, J., Lyu, H., Li, X., & Chen, J. (2021) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-021-02351-9 · Cited by 21
Zheng, H., Liu, B., Shen, J., Xie, F., Ji, Q.-M., & Zhu, X. (2022) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2022.10.013 · Cited by 22
“Simultaneously, the DLPFC region is a promising stimulation location [19,39]; future studies should further discuss the appropriate location (unilateral/bilateral) and frequency parameters on this basis [40].”
Physical mechanisms of emerging neuromodulation modalities
Karatum, O., Han, M., Erdoğan, E. T., Karamürsel, S., & Nizamoğlu, S. (2023) · Journal of Neural Engineering · doi:10.1088/1741-2552/acd870 · Cited by 21
“Today, TMS is an FDA-approved technique for the treatment of major depression disorder [101].”
BackgroundMethod
Metadata
- Authors
- McClintock, S. M., Reti, I. M., Carpenter, L. L., McDonald, W. M., Dubin, M., Taylor, S. F., Cook, I. A., O’Reardon, J., Husain, M. M., Wall, C., Krystal, A. D., Sampson, S. M., Morales, O., Nelson, B. G., Latoussakis, V., George, M. S., Lisanby, S. H., & on behalf of both the National Network of Depression Centers rTMS Task Group and the American Psychiatric Association Council on Research Task Force on Novel Biomarkers and Treatments
- Affiliations
- Duke University (US)
- Johns Hopkins University (US)
- Butler Hospital (US)
- Emory University (US)
- Weill Cornell Medicine (US)
- University of Michigan (US)
- University of California, Los Angeles (US)
- American Psychiatric Association (US)
- Mayo Clinic (US)
- Harvard University (US)
- University of Minnesota (US)
- Medical University of South Carolina (US)
- Corresponding author
- McClintock, Shawn M.
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2018-02-21
- Volume
- 79
- Issue
- 1
- Pages
- 35-48
- ISSN
- 0160-6689 (ISSN-L)
- PMC
- PMC5846193
- OpenAlex
- W2617605873
- Cited by
- 693
- References
- 120
- Citations by year
- 2026: 77 · 2025: 94 · 2024: 108 · 2023: 82 · 2022: 85 · 2021: 98 · 2020: 66 · 2019: 54 · 2018: 22
- FWCI
- 20.18
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR002384)
- National Institute of Mental Health (K23MH087739)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- repetitive transcranial magnetic stimulation, major depressive disorder, depression treatment, expert consensus recommendations, antidepressant treatment
- MeSH terms
- Contraindications, Major Depressive Disorder, Humans, Transcranial Magnetic Stimulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.